Authors: Seon, BK Kumar, S

Citation: Bk. Seon et S. Kumar, CD105 antibody for targeting of tumor vascular endothelial cells, NEW ANGIOTHERAPY, 2002, pp. 499-515

Authors: Takahashi, N Kawanishi-Tabata, R Haba, A Tabata, M Haruta, Y Tsai, H Seon, BK

Citation: N. Takahashi et al., Association of serum endoglin with metastasis in patients with colorectal,breast, and ether solid tumors, and suppressive effect of chemotherapy on the serum endoglin, CLIN CANC R, 7(3), 2001, pp. 524-532

Authors: Takahashi, N Haba, A Matsuno, F Seon, BK

Citation: N. Takahashi et al., Antiangiogenic therapy of established tumors in human skin/severe combinedimmunodeficiency mouse chimeras by anti-endoglin (CD105) monoclonal antibodies, and synergy between anti-endoglin antibody and cyclophosphamide, CANCER RES, 61(21), 2001, pp. 7846-7854

Authors: Seki, M Toi, M Kobayashi, K Shitara, K Umezawa, K Seon, BK Kan, M Rhim, JS

Citation: M. Seki et al., Differential behavior of VEGF receptor expression and response to TNP-470 in two immortalized human endothelial cell lines, INT J ONCOL, 17(3), 2000, pp. 525-533

Authors: Matsuno, F Haruta, Y Kondo, M Tsai, H Barcos, M Seon, BK

Citation: F. Matsuno et al., Induction of lasting complete regression of preformed distinct solid tumors by targeting the tumor vasculature using two new anti-endoglin monoclonalantibodies, CLIN CANC R, 5(2), 1999, pp. 371-382

Authors: Tabata, M Kondo, M Haruta, Y Seon, BK

Citation: M. Tabata et al., Antiangiogenic radioimmunotherapy of human solid tumors in SCID mice usingI-125-labeled anti-endoglin monoclonal antibodies, INT J CANC, 82(5), 1999, pp. 737-742